-
公开(公告)号：US20110190293A1
公开(公告)日：2011-08-04
申请号：US13085048
申请日：2011-04-12
IPC分类号： A61K31/5377 , C07D239/91 , A61K31/517 , A61P35/00 , C07D413/04 , C07D413/06
CPC分类号： C07D401/06 , C07D239/90
摘要： Quinazolinone compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
摘要翻译： 喹唑啉酮化合物，其药学上可接受的盐和前药; 包括药学上可接受的载体和一种或多种喹唑啉酮化合物的组合物，单独或与至少一种另外的治疗剂组合。 单独使用喹唑啉酮化合物或与至少一种其它治疗剂组合使用的方法可用于预防或治疗增殖性疾病。
-
公开(公告)号：US07939539B2
公开(公告)日：2011-05-10
申请号：US10996814
申请日：2004-11-24
IPC分类号： A61K31/517 , C07D239/88
CPC分类号： C07D401/06 , C07D239/90
摘要： Quinazolinone compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
摘要翻译： 喹唑啉酮化合物，其药学上可接受的盐和前药; 包括药学上可接受的载体和一种或多种喹唑啉酮化合物的组合物，单独或与至少一种另外的治疗剂组合。 单独使用喹唑啉酮化合物或与至少一种其它治疗剂组合使用的方法可用于预防或治疗增殖性疾病。
-
公开(公告)号：US20080249112A1
公开(公告)日：2008-10-09
申请号：US11547834
申请日：2005-04-06
IPC分类号： C07D471/04 , A61K31/519 , A61P35/00
CPC分类号： C07D471/04 , C07D239/36
摘要： The present invention relates to compounds that are useful for treating cellular proliferative diseases, for treating disorders mediated, at least in part, by KSP, and for inhibiting KSP. The invention also related to pharmaceutical compositions comprising such compounds, methods of treating cancer by the administration of such compositions, and processes for the preparation of the compounds. Compounds of the invention have the following formula: formula (I).
摘要翻译： 本发明涉及可用于治疗细胞增殖性疾病，用于治疗至少部分由KSP介导的病症和用于抑制KSP的化合物。 本发明还涉及包含这些化合物的药物组合物，通过施用这些组合物治疗癌症的方法，以及制备化合物的方法。 本发明化合物具有下式：式（I）。
-
![Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents](/abs-image/US/2008/02/05/US07326711B2/abs.jpg.150x150.jpg)
公开(公告)号：US07326711B2
公开(公告)日：2008-02-05
申请号：US10870707
申请日：2004-06-17
申请人： Weibo Wang , Ryan N. Constantine , Liana Marie Lagniton , Sabina Pecchi , Matthew T. Burger , Manoj C. Desai
发明人： Weibo Wang , Ryan N. Constantine , Liana Marie Lagniton , Sabina Pecchi , Matthew T. Burger , Manoj C. Desai
IPC分类号： A61K31/519 , A61K35/00 , C07D487/04
CPC分类号： C07D471/04
摘要： Pyridin[1,2-a]pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the pyridino[1,2-a]pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the pyridino[1,2-a]pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
摘要翻译： 吡啶并[1,2-a]嘧啶基化合物，其药学上可接受的盐和前药; 包括药学上可接受的载体和一种或多种吡啶并[1,2-a]嘧啶基化合物的组合物，单独或与至少一种另外的治疗剂组合。 单独或与至少一种其它治疗剂组合使用吡啶并[1,2-a]嘧啶基化合物在预防或治疗增殖性疾病中的方法。
-
公开(公告)号：US07345046B2
公开(公告)日：2008-03-18
申请号：US10850429
申请日：2004-05-21
IPC分类号： A61K31/519 , A61K31/13 , A61K33/24 , A61K33/42 , A61K39/395 , A61K31/337 , A61K31/497 , A61K31/436 , A61K31/506 , A61K31/555 , C07D495/04 , A61P35/04
CPC分类号： C07D239/88 , C07D495/04 , Y10S435/81
摘要： Heteroaryl-fused pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
摘要翻译： 杂芳基稠合的嘧啶基化合物，其药学上可接受的盐和前药; 包括药学上可接受的载体和一种或多种杂芳基稠合的嘧啶基化合物的组合物，单独或与至少一种另外的治疗剂组合。 将杂芳基稠合的嘧啶基化合物单独使用或与至少一种另外的治疗剂组合使用在预防或治疗增殖性疾病中的方法。
-
公开(公告)号：US08735599B2
公开(公告)日：2014-05-27
申请号：US13613977
申请日：2012-09-13
申请人： Weibo Wang , Paul A. Barsanti , Xia Yia , Rustum S. Boyce , Sabina Pecchi , Nathan Brammeier , Megan C. Phillips , Kris Mendenhall , Kelly Wayman , Liana Marie Lagnition , Ryan N. Constantine , Hong Yang , Elizabeth Mieuli , Savithri Ramurthy , Elisa Jazan , Anu Sharma , Rama Jain , Sharadha Subramanian , Paul A. Renhowe , Kenneth W. Bair , David Duhl , Annette Walter , Tinya Abrams , Kay Huh , Eric Martin , Mark Knapp , Vincent P. Le
发明人： Weibo Wang , Paul A. Barsanti , Xia Yia , Rustum S. Boyce , Sabina Pecchi , Nathan Brammeier , Megan C. Phillips , Kris Mendenhall , Kelly Wayman , Liana Marie Lagnition , Ryan N. Constantine , Hong Yang , Elizabeth Mieuli , Savithri Ramurthy , Elisa Jazan , Anu Sharma , Rama Jain , Sharadha Subramanian , Paul A. Renhowe , Kenneth W. Bair , David Duhl , Annette Walter , Tinya Abrams , Kay Huh , Eric Martin , Mark Knapp , Vincent P. Le
IPC分类号： A61K31/4174 , C07D233/00 , C07D233/54
CPC分类号： C07D233/54 , C07D233/24 , C07D233/64 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/06 , C07D405/12 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/06 , C07D417/12 , C07D417/14 , C07D498/10
摘要： The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:
摘要翻译： 本发明涉及新的取代的咪唑化合物及其药学上可接受的盐，酯或前药，新化合物的组合物和药学上可接受的载体，以及新化合物的用途。 本发明的化合物具有以下通式：
-
公开(公告)号：US20090028858A1
公开(公告)日：2009-01-29
申请号：US12242360
申请日：2008-09-30
IPC分类号： A61K39/395 , C07D215/04 , A61P35/00 , A61K31/47
CPC分类号： C07D215/12 , C07D215/18
摘要： The present invention relates to new substituted quinoline compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:
摘要翻译： 本发明涉及新的取代喹啉化合物及其药学上可接受的盐，酯或前药，新化合物与药学上可接受的载体的组合物，以及新化合物的用途。 本发明的化合物具有以下通式：
-
公开(公告)号：US07452996B2
公开(公告)日：2008-11-18
申请号：US11133509
申请日：2005-05-19
IPC分类号： C07D271/00
CPC分类号： C07D215/12 , C07D215/18
摘要： The present invention relates to new substituted quinoline compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:
摘要翻译： 本发明涉及新的取代喹啉化合物及其药学上可接受的盐，酯或前药，新化合物与药学上可接受的载体的组合物，以及新化合物的用途。 本发明的化合物具有以下通式：
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.028 秒)
